mrn

(Z)-Mirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity.

The COVID-19 Spike Protein mRNA, responsible for expressing the COVID-19 spike protein, is crucial for evaluating RNA delivery, translation efficiency, and cell viability. Positioned on the membrane surface, this spike protein facilitates virus entry into cells by binding to host cell membrane receptors and promoting membrane fusion. It serves as a significant action site for neutralizing antibodies and represents a primary focus in vaccine development [1].

CD19 CAR mRNA is designed to express the CD19 chimeric antigen receptor (CAR) protein, pivotal in chimeric antigen receptor T cell (CAR-CD19) immunotherapy. This receptor targets CD19, a membrane antigen crucial for B cell proliferation, differentiation, activation, and antibody synthesis, playing a significant role in promoting BCR signal transduction.

CD19 car mRNA-LNP, a lipid nanoparticle (LNP) encapsulating CD19 car mRNA, is instrumental in assessing RNA delivery, translation efficacy, and cell viability among other applications. This compound is pivotal for chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging the CD19 molecule - a critical membrane antigen expressed by B cells (i.e., leukocyte differentiation antigen) that plays a significant role in their proliferation, differentiation, activation, and antibody production, as well as enhancing BCR signal transduction [1] [2].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

eGFP mRNA-LNP is a lipid nanoparticle encapsulating eGFP mRNA, designed to evaluate RNA delivery, translation efficiency, and cell viability. Upon cell internalization, it expresses Enhanced Green Fluorescent Protein (eGFP), enabling detection through fluorescence microscopy or flow cytometry [1].

eGFP mRNA encodes the green fluorescent protein, originally derived from the jellyfish Aequorea victoria, and serves as a widely utilized direct detection reporter in mammalian cell culture. This protein produces a distinct bright green fluorescence, with an emission peak at 509 nm.

mRNA-Encapsulating Lipid Excipient 1 (Compound 2), a thiocarbamate-based ionizable lipid, serves as an excipient in the formulation of mRNA-encapsulating lipid nanoparticles [1].

mRNACap 2'-O-methyltransferase uses S-adenosylmethionine (SAM) as a methyl donor to add a methyl group at the 2'-O position of the first nucleotide at the 5' end of Cap-0 mRNA, resulting in the formation of a Cap-1 structure. This Cap-1 structure enhances translation efficiency and boosts subsequent protein expression.

PFM03 is an endonuclease inhibitor that specifically blocks Mre11 and is also able to reduce MRN endonuclease activity by 98%, blocking hMRN-mediated endonucleotomy and nuclear exocytosis processes on the protein-binding end of the 5 ' and 3 ' chains.

Mirin is a Mre11-Rad50-Nbs1 (MRN) complex inhibitor that inhibits MRN-dependent ATM activation without affecting ATM protein kinase activity. It also inhibits Mre11-associated exonuclease activity, thereby disrupting DNA double-strand break repair.Mirin induces cell cycle arrest in G1 phase.